Adel, Inc.
PrivateLast Round
Private Equity
Apr 9, 2026
Est. Valuation
$277.5M
Total Funding Raised
$56.02M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Adel, Inc. is a biopharmaceutical company that develops therapeutic antibodies and diagnostic systems for neurodegenerative diseases, with a primary focus on Alzheimer's disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Adel, Inc. Comparables
Compare Adel, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Oscotec Inc | 83% | |
| Amyloid Solution Inc. | 79% | |
| Prothena Corporation plc | 78% |
Adel, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Equity | Apr 9, 2026 | ||||
| Series B Extension | Jul 31, 2024 | ||||
| Series B | Oct 1, 2020 |
Adel, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Smilegate Investment | Series B Extension, Private Equity |
| Korea Investment Partners | Private Equity |
| Samsung Securities | Private Equity |
| DS Asset Management | Private Equity |
| Mirae Asset Securities | Private Equity |
| Timefolio Asset Management | Private Equity |
| Samsung Venture Investment | Private Equity |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 37% MoM, reaching 11.2K.
- Apr 27, 2026
Grew 50% QoQ, from 6 to 9 employees.
Adel, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Adel, Inc.'s valuation, stock price, and market status.
Is Adel, Inc. a public or private company?
Adel, Inc. is a private company.
What is the current stock price of Adel, Inc.?
Adel, Inc. is a private company, so its shares have no public market price. Caplight tracks Adel, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Adel, Inc. worth (valuation)?
Adel, Inc.'s valuation is estimated at $277.5M based on funding round data.
Can I buy Adel, Inc. stock?
Adel, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Adel, Inc.'s last funding round?
Adel, Inc.'s most recent funding round was Private Equity on April 9, 2026.
Who are the main investors in Adel, Inc.?
Key investors in Adel, Inc. include Stonebridge Ventures.
Will Adel, Inc. IPO soon?
No public IPO plans have been announced for Adel, Inc..
How can I track Adel, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Adel, Inc.'s shares on secondary markets.